An ongoing clinical trial foresees the use of CD19 CAR-T cells in combination with PD-1 monoclonal antibody (tislelizumab) for the treatment of patients with diffuse large B cell lymphoma that relapsed or are refractory to the standard therapy (Figure 3) (NCT04381741) (Wang et al., 2021). Here, CD19 is linked to diffuse large B-cell lymphoma.